Analyst Ratings February 12, 2026

Morgan Stanley Keeps Huntington Bancshares as Top Pick Despite Trimmed 2027 Guidance

Analysts stick with constructive ratings after Cadence merger; bank must now show mid-year revenue momentum and deliver on synergies

By Ajmal Hussain HBAN
Morgan Stanley Keeps Huntington Bancshares as Top Pick Despite Trimmed 2027 Guidance
HBAN

Morgan Stanley has reaffirmed an Overweight rating and a $21.00 price objective on Huntington Bancshares (HBAN), maintaining the stock as its Top Pick even after the bank reduced its 2027 EPS outlook. Huntington lowered its 2027 EPS range to $1.90-$1.93 from $2.00 while lifting revenue targets and signaling reinvestment of some merger synergies. The bank's expanded footprint following the Cadence Bank merger pushes the need for visible revenue gains and synergy realization into the middle of the year.

Key Points

  • Morgan Stanley reaffirms Overweight rating and $21.00 price target on Huntington Bancshares, keeping it as a Top Pick.
  • Huntington trimmed 2027 EPS guidance to $1.90-$1.93 from $2.00 while raising revenue targets and reinvesting some merger synergies.
  • The Cadence Bank merger expands Huntingtons assets to about $279 billion, adds 390 branches and increases its footprint in Texas and the Southeast.

Morgan Stanley has once again rated Huntington Bancshares (NASDAQ: HBAN) as Overweight and left its price target at $21.00, continuing to list the bank as one of its preferred holdings despite a recent downward revision to the companys 2027 earnings outlook. The $21.00 target implies roughly 17% upside from the stocks current level of $17.93, and market data indicates the shares trade marginally below what InvestingPro deems fair value.

Huntington adjusted its 2027 EPS guidance lower, moving from $2.00 to a narrowed range of $1.90 to $1.93. Management attributed the adjustment in part to a lower provision for acquired assets while setting loftier revenue goals, noting that some expected synergies will be reinvested to support revenue initiatives. Over the trailing twelve months, InvestingPro data shows Huntington delivered solid revenue growth of 10.88%.

Those changes have shifted the timeline for key stock catalysts. Where investors and analysts previously expected more immediate progress in the first quarter, the companys updated targets place the burden of proof into mid-year. Huntington now needs to show persistent revenue momentum and demonstrate that promised synergies from its merger are being converted into measurable financial benefits.

Market performance has been mixed. The shares have returned approximately 10.81% over the last six months, based on InvestingPro figures, but sentiment among analysts has not been uniformly upward; eleven analysts have trimmed their earnings estimates for the bank. Morgan Stanley nonetheless views the company as having room to reach its targets, citing a path that includes roughly 10% growth in core fees and about $150 million in synergies. The firm does not, however, expect Huntington to outperform those assumptions.

Investor attention will likely turn to the banks upcoming conference on March 10-11, where Huntington is expected to provide more granular detail on how it plans to extract revenue synergies and other approaches to meeting its financial objectives. That event will be a focal point for analysts and investors seeking clarity on execution and timing.

The strategic context for these expectations is the completed merger with Cadence Bank, which materially increases Huntingtons scale and geographic reach. The combination raises the banks total assets to about $279 billion, with $221 billion in deposits and $187 billion in loans, and brings 390 branches into the network. The merger also materially expands Huntingtons presence across Texas and the Southeast.

Analyst coverage around the deal has skewed mostly positive. Besides Morgan Stanleys reiterated Overweight rating and $21.00 price target, Evercore ISI has started coverage with an Outperform rating, and Truist Securities has increased its price target to $21.00 while keeping a Buy rating. Those stances reflect optimism about Huntingtons post-merger growth prospects even as the bank works through near-term expense and integration dynamics.

At the same time, Huntingtons shares have weakened since the companys most recent earnings release, underscoring the complexity of integrating large acquisitions while managing investor expectations. The next several months will be critical for the bank to show that its expanded footprint and reinvestment strategy translate into sustained revenue acceleration and realized cost synergies.


What to watch next

  • Details and modeling updates following the March 10-11 investor conference, particularly on revenue synergies and alternative approaches management may present.
  • Quarterly results and forward commentary that indicate whether revenue momentum is tracking toward the revised mid-year catalysts.
  • Any updates to synergy realization timelines and the magnitude of reinvestment versus cost savings.

Risks

  • Execution risk around converting projected synergies into measurable savings and revenue, which is critical for meeting revised targets - impacts banking and financial services sectors.
  • Potential for further analyst downgrades or investor disappointment if mid-year revenue momentum does not materialize, affecting bank stock performance and regional banking sentiment.
  • Near-term share underperformance driven by elevated expenses or slower-than-expected integration outcomes as Huntington absorbs Cadence and reinvests synergies - relevant to equity markets and credit-focused investors.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026